Population pharmacokinetic analysis of etrolizumab in patients with moderately-to-severely active ulcerative colitis [2] CPT Pharmacometrics Syst Pharmacol. 2022 Sep;11(9):1244-1255 Moein A, Lu T, Jönsson S, Ribbing J, Kassir N, Zhang W, Sperinde G, Zhang R, Tang M, Oh YS, Bruno R. GIInflammationJournalPharmacometrics Pharmetheus Affiliates Senior Consultant Siv Jönsson See bio Principal Consultant & Client Operations Expert Jakob Ribbing See bio
